In the SURPASS-2 study, tirzepatide 15 mg resulted in a faster and greater decline in body weight ( 5.5 kg) compared to semaglutide 1.0 mg, more than doubling the proportion of patients achieving at least 10% weight loss (57% vs 24%) [3]
Key points Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus Wegovy is FDA-approved for weight loss, while Ozempic and Rybelsus are for type 2 diabetes Most people lose about 15% of their body weight over 17 months with Wegovy All 3 semaglutide medications stay in your system for 5 weeks and share similar side effects, like nausea and digestive issues Wegovy now treats more than weight loss Let's get straight to the point
Their combination may seem complementary on paper, particularly in athletic contexts that combine endurance and explosive efforts
Migraines impact an estimated 14 to 15 percent of the global population, and yet the few medications we have on hand do not work for everybody
Comparative studies and head-to-head trials are essential for understanding the distinct attributes of each GLP-1 RA, shedding light on their efficacy, dosing, and side effects to better tailor treatment plans to individual patient needs